Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,822 across all filing types
Latest filing 2021-02-25 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction in company shares by a member of the Board of Directors (Jonathan Peacock). It explicitly references Article 19 of Regulation No. 596/2014 on Market Abuse, which is the standard regulatory framework for reporting insider/director dealings. The content details the specific financial instrument, volume, price, and date of the transaction, fitting the definition of a Director's Dealing (DIRS) filing.
2021-02-25 English
6-K
Foreign Filer Report
2021-02-23 English
6-K
Foreign Filer Report
2021-02-23 English
Genmab announces initiation of share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a formal company announcement from Genmab regarding the initiation of a share buy-back program. It details the purpose, timeframe, and terms of the repurchase of its own shares. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2021-02-23 English
Transaction in Own Shares 2021
Transaction in Own Shares Classification · 100% confidence The document is titled "Genmab announces initiation of share buy-back program" and details the terms, purpose, and timeframe for repurchasing up to 200,000 shares. This action directly relates to the company's capital structure management, specifically share repurchases. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although it is an announcement, the core subject matter is the transaction itself, making POS a more specific fit than the general 'RPA' or 'RNS'. The document length (7052 chars) is substantial enough to be the primary announcement rather than just a pointer to a report.
2021-02-23 English
Annual Report 2020
Annual Report Classification · 100% confidence The document is clearly identified as the '2020 Annual Report' for Genmab A/S. It contains a comprehensive review of the company's business, strategy, financial statements, and auditor's report, which aligns perfectly with the definition of a 10-K (Annual Report). FY 2020
2021-02-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.